Preclinical Trial-on-Chip based Cytokine Release Syndrome (CRS) Assessment Service

Online Inquiry

Background Service What We Can Offer Workflow HighlightsFAQs Contact

Current challenges in immuno-oncology include the inability of traditional preclinical models to reliably predict life-threatening CRS, leading to high clinical attrition and safety risks. Creative Biolabs' Preclinical Trial-on-Chip-based Cytokine Release Syndrome (CRS) Assessment Service directly addresses this translational gap. This service leverages advanced microfluidic organ-on-chip platforms that integrate human vascular endothelium, patient-relevant immune cells, and physiological flow to create a dynamic, human-relevant model of systemic inflammation. By providing high-fidelity, mechanistic data on cytokine storm kinetics and endothelial activation, we empower you to de-risk your immunotherapy candidates, optimize therapeutic windows, and accelerate safer therapies into the clinic.

Introduction

Advances in immuno-oncology are critically impeded by the life-threatening risk of CRS, a systemic hyperinflammatory complication triggered by immune-activating therapies. To address this, the field of safety assessment is transitioning decisively from conventional, low-predictivity models, including static peripheral blood cell assays and non-translational animal studies, to sophisticated, human-relevant in vitro systems. These next-generation platforms are engineered to model the sequential key events of the CRS adverse outcome pathway, spanning initial T-cell engagement, endothelial cell activation, and the ensuing cytokine storm. By facilitating precise, mechanism-driven hazard characterization and predictive biomarker identification, such advanced models are indispensable for de-risking drug candidates, establishing safer first-in-human (FIH) dosing, and enhancing the clinical safety profile of T-cell engagers and related immunotherapies.

Fig.1 Adverse immune activation pathway in cytokine release syndrome. (OA Literature) Fig.1 Mechanistic cascade of immunotherapy-induced cytokine release syndrome.¹

Preclinical Trial-on-Chip-based Cytokine Release Syndrome (CRS) Assessment Service at Creative Biolabs

Our platform offers an unparalleled view into the intricate immune dynamics driving systemic inflammatory responses. Leveraging Trial-on-Chip technology, we generate kinetic cytokine release profiles and identify clinically relevant "off-target" immune activation prior to first-in-human studies. This approach directly resolves the "speed-safety paradox" inherent to accelerated immunotherapy development by detecting early pro-inflammatory signals, including those induced by residual manufacturing components or hypermetabolic activity, that could precipitate cytokine release syndrome.

What We Can Offer

Our Preclinical Trial-on-Chip-based CRS Assessment Service integrates cutting-edge technologies into a holistic, physiologically relevant testing platform designed to predict and de-risk the complex inflammatory cascade of Cytokine Release Syndrome.

Featured services of preclinical trial-on-chip-based CRS assessment service at Creative Biolabs. (Creative Biolabs Original)

Our Service Process

Required Starting Materials:

Target profiles. Therapeutic Candidate: CAR-T cells, TCR-T cells, or bispecific antibodies.
Target Information: Details on the target antigens and relevant cell lines or primary tumor tissues.
Manufacturing Specs: Brief details on the manufacturing protocol to calibrate the assay sensitivity.

Key Steps:

Workflow of preclinical trial-on-chip-based CRS assessment service at Creative Biolabs. (Creative Biolabs Original)

Final Deliverables: Upon completion of the analysis, you will be provided with an integrated Safety Profile Assessment Report. This document presents a comprehensive dossier containing multiplexed cytokine/chemokine profiling data and a standardized toxicity grading evaluation.

Key Advantages

Tailored Biofabrication Solutions: We provide custom-designed microfluidic chip platforms engineered to precisely replicate relevant tissue-specific barriers, cognate antigen profiles, and donor-matched primary immune cell populations.
Dynamic System-Wide Profiling: Our workflow integrates continuous, high-resolution live-cell imaging with automated time-point sampling of perfusate, enabling the precise temporal mapping of cytokine storm initiation and propagation.
Stringent Quality and Process Assurance: All operations adhere to a Quality-by-Design (QbD) framework under rigorous aseptic conditions, guaranteeing the sustained viability and functional fidelity of primary human cellular components throughout the assay duration.

FAQs

Q1: How does your Trial-on-Chip model compare to standard NHP (Non-Human Primate) studies?

A1: While NHP models are traditionally the gold standard, they often lack human-specific cytokine kinetics. Our chip-based system utilizes human primary cells, providing a higher degree of immunological fidelity for human-specific targets at a fraction of the cost.

Q2: Can this service help predict neurotoxicity (ICANS) as well?

A2: Yes. By incorporating blood-brain barrier (BBB) components into the chip architecture, we can monitor cytokine penetration and endothelial activation related to ICANS.

Why Choose Us?

We offer the most physiologically relevant CRS assessment by uniquely integrating vascular endothelium and physiological shear stress in a microfluidic platform, moving beyond static PBMC assays. This system provides a human-vascularized model that can differentiate manageable from severe cytokine storm profiles, validated against clinical outcomes. Choose us to de-risk your immunotherapy candidates with predictive, actionable safety data for precise dosing and molecular optimization.

Customer Reviews

"Integrating the Trial-on-Chip CRS platform provided crucial insight into tumor-specific versus off-target cytokine activation. The physiological flow dynamics revealed context-dependent responses absent in conventional static assays."

— Dr. A***n L.

"The platform enabled a more efficient translational pathway. Its detailed analysis of monocyte-mediated TNF‑α signaling was explicitly noted as a strength during our pre‑IND regulatory review."

— Ms. S***h M.

"The system critically informed our candidate triage. We deprioritized a lead that appeared safe in murine models but elicited a pronounced IL‑1β response in the human‑relevant chip environment."

— Mr. R***t K.

How to Contact Us?

To obtain a customized quote for our Preclinical Trial-on-Chip CRS Assessment Service, please contact our expert team. We will promptly provide a detailed proposal, including scope, timelines, and pricing tailored to your specific candidate and target.

Reference

Perkins Ethan, Cooper Christopher et al. "Perspective of using in vitro models to understand immunotherapy-induced cytokine release syndrome." Frontiers in Immunologyvol. 16. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3389/fimmu.2025.1732193.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.